Quarterly Result31 May 2025, 05:32 am
Fredun Pharmaceuticals Reports Robust Q4 & FY25 Performance with 41.8% YoY Total Income Growth and 33.2% YoY PAT Growth
AI Summary
Fredun Pharmaceuticals Limited, a leading provider of pharmaceuticals and innovative healthcare solutions, announced their financial results for the quarter and year ended March 31, 2025. The company reported a 41.8% YoY growth in total income for Q4FY25, with EBITDA and PAT growing by 56.2% YoY and 39.7% YoY respectively. For FY25, total income, EBITDA, and PAT grew by 30.7%, 41.6%, and 33.2% respectively. Key business updates during Q4FY25 include foray into large animal veterinary products, international expansion of Freossi Petcare Division, tender award from TNMSC for generic pharma products, and order book updates.
Key Highlights
- Q4FY25 Total Income stood at Rs. 167.4 Cr, a growth of 41.8% YoY
- Q4FY25 EBITDA at Rs. 17.4 Cr, a growth of 56.2% YoY
- Q4FY25 Profit after Tax stood at Rs. 7.1 Cr, a growth of 39.7% YoY
- FY25 Total Income stood at Rs. 456.3 Cr, a growth of 30.7% YoY
- FY25 Profit After Tax stood at Rs. 20.8 Cr, a growth of 33.2% YoY